Copyright
©The Author(s) 2016.
World J Diabetes. Dec 15, 2016; 7(20): 572-598
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Figure 8 Effects of obesity on glucagon-like peptide 1 responses post oral glucose load and post-prandial.
Obese subjects consistently demonstrate reduced glucagon-like peptide 1 (GLP-1) secretory responses following a 75-g oral glucose load compared to lean controls. Post-prandial GLP-1 secretory responses in obese subjects are conflicting, with some studies observing significant reductions and others observing no change[168-178] when compared to lean controls.
- Citation: Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598
- URL: https://www.wjgnet.com/1948-9358/full/v7/i20/572.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i20.572